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Abstract
We have shown previously that replacement of the spike (S) gene of the apathogenic IBV strain Beau-R with that from the
pathogenic strain of the same serotype, M41, resulted in an apathogenic virus, BeauR-M41(S), that conferred protection
against challenge with M41 [1]. We have constructed a recombinant IBV, BeauR-4/91(S), with the genetic backbone of Beau-
R but expressing the spike protein of the pathogenic IBV strain 4/91(UK), which belongs to a different serogroup as
Beaudette or M41. Similar to our previous findings with BeauR-M41(S), clinical signs observations showed that the S gene of
the pathogenic 4/91 virus did not confer pathogenicity to the rIBV BeauR-4/91(S). Furthermore, protection studies showed
there was homologous protection; BeauR-4/91(S) conferred protection against challenge with wild type 4/91 virus as shown
by the absence of clinical signs, IBV RNA assessed by qRT-PCR and the fact that no virus was isolated from tracheas removed
from birds primarily infected with BeauR-4/91(S) and challenged with IBV 4/91(UK). A degree of heterologous protection
against M41 challenge was observed, albeit at a lower level. Our results confirm and extend our previous findings and
conclusions that swapping of the ectodomain of the S protein is a precise and effective way of generating genetically
defined candidate IBV vaccines.
Citation: Armesto M, Evans S, Cavanagh D, Abu-Median A-B, Keep S, et al. (2011) A Recombinant Avian Infectious Bronchitis Virus Expressing a Heterologous
Spike Gene Belonging to the 4/91 Serotype. PLoS ONE 6(8): e24352. doi:10.1371/journal.pone.0024352
Editor: Volker Thiel, Kantonal Hospital St. Gallen, Switzerland
Received June 24, 2011; Accepted August 5, 2011; Published August 30, 2011
Copyright:  2011 Armesto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Department of Environment, Food and Rural Affairs (DEFRA; http://www.defra.gov.uk/) project code OD0717, the
Biotechnology and Biological Sciences Research Council (BBSRC; http://www.bbsrc.ac.uk/) and Intervet Schering-Plough UK. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: This work was supported in part by Intervet Schering-Plough UK. There were no consultancy payments or products in development from
the submitted work. This does not alter the authors’ adherence to all PLoS ONE policies on sharing data and materials.
* E-mail: paul.britton@iah.ac.uk
Introduction
Avian infectious bronchitis virus (IBV) is a gammacoronavirus,
subfamily Coronavirinae, family Coronaviridae, Order Nidovirales [2]
and is the aetiological agent of the acute highly contagious poultry
disease infectious bronchitis (IB) [3–6]. IBV is a highly infectious
pathogen of domestic fowl that replicates primarily in epithelial
cells of the respiratory tract [7,8] causing IB characterised by nasal
discharge, snicking, tracheal ciliostasis and rales in chickens [1].
Although IBV is primarily associated with respiratory tract
infections, it is also responsible for major economic losses to
poultry industries worldwide as a result of poor weight gain and
decreased egg production [9]. In addition, some isolates have been
found to be associated with renal disease and can be highly
nephropathogenic [10–12].
Coronaviruses are enveloped viruses that replicate in the cell
cytoplasm and contain an unsegmented, single-stranded, positive-
sense RNA genome of 28 to 32 kb [13–15]. IBV, like all
coronaviruses, contains the four structural proteins; spike glyco-
protein (S), small membrane protein (E), integral membrane
protein (M) and nucleocapsid protein (N), which interacts with the
genomic RNA. The coronavirus S glycoprotein is a type I
glycoprotein that oligomerises in the endoplasmic reticulum [16]
to form trimers [17], which constitute the coronavirus virion spikes
observable by electron microscopy. The S protein is assembled
into virion membranes, through non-covalent interactions with the
M protein [18], and is responsible for binding to the target cell
receptor and fusion of the viral and cellular membranes, fulfilling a
major role in the infection of susceptible cells [19].
All coronavirus S glycoproteins consist of four domains; a signal
sequence that is cleaved during synthesis; the ectodomain, which is
present on the outside of the virion particle; the transmembrane
region responsible for anchoring the S protein into the lipid bilayer
of the virion particle; and the cytoplasmic tail. The IBV S
glycoprotein (1162 amino acids) is cleaved into two subunits, S1
(535 amino acids, 90-kDa) comprising the N-terminal subunit of
the S protein and S2 (627 amino acids, 84-kDa) comprising the C-
terminal subunit of the S protein. The S2 subunit associates non-
covalently with the S1 subunit and contains the transmembrane
and C-terminal cytoplasmic tail domains. The S1 subunit contains
the receptor-binding activity of the S protein [20,21]. The
ectodomain region of the S2 subunit contains a fusion peptide-
like region [22] and two heptad repeat regions involved in
oligomerisation of the S protein [23] and is required for entry into
susceptible cells [24–26].
We have previously shown, using our IBV reverse genetics
system [27–29], that replacement of the ectodomain of the IBV
Beaudette S glycoprotein with the corresponding region from the
pathogenic IBV M41-CK did not confer virulence to Beau-R but
did result in a rIBV, BeauR-M41(S), which had the tissue tropism
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BeauR-M41(S) were found to be protected against clinical disease
following challenge with IBV M41-CK, whereas chickens
vaccinated with Beau-R were not protected against challenge
with M41-CK [1]. These results indicated that BeauR-M41(S) was
able to induce a protective response against homologous challenge
with M41-CK, whereas Beau-R was unable to induce a protective
response even though both viruses belong to the same,
Massachusetts, serogroup. Beau-R is a molecular clone of the
Beaudette isolate, an IBV that was attenuated after several
hundred passages in embryonated hen’s eggs [31], which not only
resulted in loss of virulence, but has also been implicated in loss of
immunogenicity. Our work has shown that infectious virus was not
recovered from tracheal cells following infection of chickens with
Beau-R and BeauR-M41(S) or for the H120 [32] vaccine strain of
IBV [1]. The genome of BeauR-M41(S) is isogenic with Beau-R
and the fact that it is able to protect against homologous challenge
indicates that Beaudette or Beaudette-based viruses are able to
replicate in chickens raising the possibility that the inability of
Beaudette to protect against a virus from the same serotype is not
due to the fact the virus cannot replicate in the chicken, but due to
an immunogenic mis-match of the Beaudette S glycoprotein with
other Massachusetts serotype viruses. Replication of IBV and IBV
vaccines in the chicken Harderian gland has been implicated in
the induction of immunity against IBV [32–35] indicating that
IBV vaccines are able to replicate in this tissue. It is possible that
some other protein derived from Beaudette in combination with
the M41 S glycoprotein may overcome the block in protection
associated with Beau-R. In this paper we describe the use of our
IBV reverse genetics system to further investigate the role of the
IBV S glycoprotein in protection. A rIBV was generated in which
the ectodomain region of Beaudette S glycoprotein gene was
replaced with the corresponding sequence from IBV 4/91(UK); a
pathogenic strain of IBV that belongs to a different serogroup as
Beaudette and M41, that has been an important problem to the
poultry industry since the 1990s [6].
Materials and Methods
Ethics Statement
All animal experimental protocols were carried out in strict
accordance with the UK Home Office guidelines and under
licence granted for experiments involving regulated procedures on
animals protected under the UK Animals (Scientific Procedures)
Act 1986. The experiments were performed in the IAH Home
Office licensed (PCD30/4301) experimental animal house facilities
and were approved by the IAH ethical review committee under
the terms of reference HO-ERP-01-1, using chickens obtained
from the IAH Poultry Production Unit.
Cells and viruses
The pathogenic IBV strain 4/91(UK) used in this study was a
gift from Intervet UK Ltd and was grown in 10-day-old specific
pathogen free (SPF) Rhode Island Red (RIR) embryonated hen’s
eggs obtained from the Institutes’ poultry production unit; primary
chick kidney (CK) cells are refractory for growth of IBV 4/
91(UK). M41-CK was derived from the pathogenic M41 strain of
IBV following adaptation in CK cells [36,37]. Vaccinia viruses
(VV) were routinely grown and titrated on Vero cells as described
previously, whilst large stocks for DNA isolation were prepared
from infected BHK-21 cells [28,29]. Tracheal organ cultures
(TOCs) were prepared from 19-day-old SPF RIR chicken
embryos [36,38]. Titrations of virus infectivity were performed
in TOCs and the titres expressed as the 50% (median) ciliostatic
doses (CD50) as described previously [1].
Construction of chimaeric spike gene
The sequence corresponding to the chimaeric S gene, consisting
of 3327 nucleotides from the ectodomain and transmembrane
domain from IBV 4/91(UK) S gene sequence (GenBank accession
number JN192154) and 136 nucleotides corresponding to the
cytoplasmic domain from Beau-R (GenBank accession number
AJ311317), was produced as described in Fig. 1. The 4/91-derived
S gene sequence was amplified by RT-PCR using RNA extracted
from the allantoic fluid of embryonated eggs infected with IBV 4/
91(UK) and 4/91-derived primers containing PacI( 5 9) and BspHI
(39) restriction sites. The chimaeric S gene was generated using the
PacI and BspHI sites present at the same respective positions in
both virus-derived sequences (Fig. 1). The PacI site at nucleotide
20337 is 30 nucleotides proximal of the S gene initiation codon
and 21 nucleotides distal of the S gene transcriptional regulatory
sequence, the BspHI site at nucleotide 23714 is at the end of the
transmembrane domain. In brief, the 4/91-derived 3389-nucleo-
tide PacI-BspHI cDNA fragment was used to replace the
corresponding M41 S sequence in pGPT-M41S [28] generating
pGPT-4/91S. The pGPT-M41S vector was digested with PacI and
BspHI to remove the M41 sequence and used for insertion of the
PacI-BspHI 4/91-derived cDNA (Fig. 1). The resulting plasmid,
pGPT-4/91S consisted of 1245 nucleotides of the 39-end of the
replicase gene of Beau-R, followed by the 4/91-Beaudette
chimaeric S gene and 944 nucleotides of gene 3 and M gene of
Beau-R (Fig. 1). RT-PCR products were sequenced using a variety
of oligonucleotides covering the S gene sequence and adjoining
regions of the Beaudette sequence and used for the assembly of 4/
91-derived S gene sequence using Gap4 of the Staden Sequence
Software Programs [39].
Generation of recombinant vaccinia viruses containing
modified IBV cDNAs
The 4/91 S sequence within pGPT-4/91S was introduced into
the IBV genome within recombinant vaccinia virus (rVV) VV-
BeauR-DS, which contains the complete Beau-R genome, minus
the S sequence [28]. This was achieved by homologous
recombination using the transient dominant selection system
(TDS) [28]. In brief, Vero cells (,50% confluent) were infected
with VV-BeauR-DS at a MOI of 0.2 and transfected 2 h later with
5 mg of pGPT-4/91(S) in the presence of lipofectin (Invitrogen).
Resultant phenotypically guanine xanthine phosphoribosyltrans-
ferase positive (GPT
+) rVVs were then selected by three rounds of
plaque purification using Vero cells in the presence of 25 mg/ml
mycophenolic acid (MPA), 250 mg/ml xanthine and 15 mg/ml
hypoxanthine. Next, randomly selected MPA-resistant GPT
+
rVVs were grown and plaque purified three times in Vero cells
in the absence of selection medium. This process resulted in a
second recombination event causing the loss of the GPT gene from
the rVVs; leading to either generation of rVVs containing IBV
cDNA corresponding to the original sequence (BeauR-DS) or to a
full-length BeauR-4/91(S) cDNA. PCR amplification of the DNA
from these rVVs was used to (a) confirm the absence of the GPT
gene, using GPT-specific primers; and (b) to determine the
presence of the chimaeric S gene sequence, using 4/91-specific S
gene primers. Recombinant VVs, that were GPT negative and
generated PCR products of the expected size from a 4/91 S gene
sequence, were further screened by sequence analysis of different
regions of the S1 and S2 subunits of the chimaeric S gene to
confirm that the required S gene had been introduced into
the IBV genomic cDNA. A rVV, rVV-BeauR-4/91(S), which
Recombinant IBV Expressing Heterologous S Protein
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e24352contained a full-length IBV cDNA consisting of the genomic
background of Beau-R but with the ectodomain sequence of the
4/91(UK) S gene sequence, was chosen and used for further work.
Recovery of an infectious rIBV expressing a chimaeric S
protein
DNA from rVV-BeauR-4/91(S) was purified and initially used to
rescue rIBVs in CK cells as previously described [28]. Cell lysate
(0.1 ml) from the infected and transfected CK cells (P0)w a su s e dt o
infect 10-day-old SPF embryos. The infected embryos were
incubated at 37uC for 48 h, after which they were placed at 4uC
overnight. Allantoic fluid was collected (EP1) and waspassed afurther
five times in 10-day-old SPFembryos and the resultant rIBV, BeauR-
4/91(S), was used in subsequent experiments. RNA was extracted
from the allantoic fluid of infected eggs using the RNeasyH method
(Qiagen) for the amplification of part of the S gene by RT-PCR
(Ready-To-Go
TM RT-PCR beads) to confirm the identity of the
rIBV by sequence analysis. A stock of BeauR-4/91(S) was produced
in 10-day-oldSPFembryonated eggs, final titre 2610
5.6CD50 perml,
which was used for subsequent in vivo experiments.
In vivo analysis of the rIBVs
Virus stocks for the in vivo experiments were prepared from 10-
day-old SPFembryonated RIReggs and titrated inTOCs; the titres
of the stock viruses were 4/91(UK) 5.4 log10 CD50, BeauR-4/91(S)
5.6 log10 CD50 and M41-CK 6.0 log10 CD50 in a volume of 1 ml.
Five groups (n=13) of 8-day-old SPF RIR chickens were used for in
vivo analysis of rIBV BeauR-4/91(S). The chickens were housed in
negative-pressure, temperature-controlled HEPA-filtered isolation
rooms, with each group housed in a separate room. Three groups of
birds were inoculated via the conjunctival (eye drop) and intranasal
routes with 3.6 log10 CD50 of BeauR-4/91(S) in 0.1 ml serum-free
BES (N, N-Bis(2-hydroxyethyl)-2-aminoethanesulphonic acid) con-
taining medium. The other two groups were inoculated withserum-
free BES medium as controls. Three weeks post-infection, the three
groups that had been infected with BeauR-4/91(S) were challenged
using 3.6 log10 CD50 in a total of 0.1 ml with either IBV 4/91(UK),
IBV M41-CK or mock-challenged and the two mock-infected
groups were either mock challenged or challenged with 4/91(UK);
in all cases the challenge viruses were administered via the
conjunctival and intranasal routes.
Figure 1. Schematic diagram for the construction of the chimaeric 4/91 S gene. Two DNA fragments of 2042 and 2300-nucleotides were
generated from the IBV 4/91(UK) S gene sequence that overlapped at an internal AlwNI site. The 2042-nucleotide cDNA, corresponding to the 59 half
of the 4/91 S gene was digested with PacI and AlwNI and ligated to the AlwNI-BspHI fragment generated from the 2300-nucleotide cDNA
corresponding to the 39 half of the 4/91 S gene. The 4/91-derived 3389-nucleotide PacI-BspHI cDNA was then used to replace the corresponding M41-
CK S gene sequence in pGPT-M41S generating a new chimaeric S gene sequence with the ectodomain derived from 4/91(UK) and the cytoplasmic
domain from Beau-R in pGPT-4/91S. Plasmid pGPT-4/91S was used to insert the 4/91 chimaeric S gene into the Beau-R genome by homologous
recombination utilising the Beau-R replicase and gene 3 sequences, 59 and 39 to the S gene sequence, respectively, using rVV VV-BeauR-DS by TDS.
doi:10.1371/journal.pone.0024352.g001
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The clinical signs used to determine pathogenicity were snicking
(a sound similar to a sneeze), tracheal rales (a sound emanating
from the bronchi, also detected by vibrations when holding a
chick), wheezing (dyspoena), nasal discharge, watery eyes and
ciliary activity of the trachea [1]. Chicks were observed daily for
clinical signs; snicks were independently counted by two persons
over a 2 min period. Birds were checked individually for the
presence of tracheal rales, nasal discharge, watery eyes and
wheezing. Tracheas were removed from three randomly selected
chickens from each group at 4, 5 and 6 days post-challenge for
assessment of ciliary activity. Ten 1 mm sections were cut from
three different regions of each trachea and the level of ciliostasis of
each tracheal section was determined using light microscopy.
Detection of viral RNA from infected chickens
The remaining regions of the tracheas from the infected birds
were divided in two, one part was stored in RNAlaterH (Ambion) to
be used for RNA extraction, and the other was kept in PBS to be
used for virus isolation. For RNA extraction, trachea sections
stored in RNAlaterH were placed in RNA lysis buffer followed by
disruption and homogenisation in TissueLyser II (Qiagen) for
2 min at 25 Hz. Total RNA was extracted using the RNeasyH kit
(Qiagen), following the manufacturer’s instructions, and was used
as a template for real-time RT-PCR, using primers IBV59GU391
(391GCTTTTGAGCCTAGCGTT408) and IBV59GL533 (533GC-
CATGTTGTCACTGTCTATTG512) and a TaqmanH dual-
labelled probe IBV59 G probe (FAM-494CACCACCAGAA-
CCTGTCACCTC473-TAM) [40] using nucleotide positions of
IBV M41 (GenBank accession number AY851295). Both primers
and probe were synthesised by SIGMA. The 10 ml real-time RT-
PCRs consisted of 5 ml of 2x FAST Master mix (TaqmanH Fast
Universal PCR Master Mix (2x), No AmpErase, Applied
Biosystems), 0.25 ml of Multiscribe Enzyme (Applied Biosystems),
primers at a final concentration of 1 mM, probe at 5 mM, 2.5 mlo f
RNA and water. All reactions were performed in triplicate in a
7500FAST TaqmanH machine (Applied Biosystems) at 48uC for
30 min; 95uC for 20 sec; 95uC for 3 sec; 40 cycles of 95uC for
3 sec followed by 60uC for 3 sec. Amplification plots were
analysed using Applied Biosystems Sequence Detection Software
version 1.3.1.21 (2001–2005 Applied Biosystems).
Viral isolation
Tracheal sections stored in PBS were freeze-thawed and
homogenised using the TissuelyserII (Qiagen).The resulting tracheal
suspensions were centrifuged and the supernatants used to infect
TOCs. Tracheal suspensions were prepared separately from three
birds (except for the mock infected:4/91-challenged group, n=2) per
sampling day (days 4, 5 and 6 after challenge) for the BeauR-4/
91(S):4/91 and BeauR-4/91(S):M41 groups. Six TOCs were infected
with 100 ml of the corresponding tracheal suspension. After infection
at 37uC for 1 h, 0.5 ml of medium was added and the TOCs
incubated at 37uC for 7 days during which they were regularly
observed for ciliary activity. To compare the ciliary activity results
ANOVA analysis was performed followed by the post-hoc Dunnett’s
multiple comparison test using GraphPad Prism version 5.03
(GraphPad Software Inc. 1992–2010, www.graphpad.com).
Results
Generation of a rIBV with the genomic backbone of
Beau-R but expressing the S gene from 4/91(UK)
Sequence analysis of the IBV 4/91(UK) S gene identified 555
nucleotide differences and a 6-nucleotide insertion when
compared to the Beau-R S gene sequence, corresponding to a
total of 201 amino acid differences between the two S
glycoproteins with two extra amino acids within the 4/91 S
glycoprotein (Fig. 2). There is one amino acid difference between
the cytoplasmic domains of the two viruses, M
1131 R I
1133 for
Beau-R and 4/91(UK), respectively. Overall, the primary
translation products of the two S genes are 1164 and 1162
amino acids for 4/91(UK) and Beau-R, respectively, with an
identity of 82.7% between the two S proteins; 75.3% and 89.1%
identity for the S1 and S2 subunits, respectively. A chimaeric S
gene, consisting of the signal sequence, ectodomain and
transmembrane regions derived from IBV 4/91(UK) and the
cytoplasmic tail from Beau-R, was produced. The last 137
nucleotides of the Beaudette S gene, comprising of the
cytoplasmic domain, were retained to maintain any interaction
[18] of the S protein C-terminal domain with the other
Beaudette-derived proteins. The transmembrane regions between
the two S glycoproteins only contained one amino acid
difference, T
1104 R I
1106 for Beau-R and 4/91(UK), respectively.
A plasmid, pGPT-4/91S, containing the chimaeric S gene with
the above characteristics was generated and used to produce a
full-length IBV-derived cDNA, containing the complete genomic
sequence of Beau-R but with the chimaeric S gene within the
vaccinia virus genome, using the TDS method. This was achieved
using a Beau-R-DS receiver sequence and a donor sequence in
pGPT-4/91S (Fig. 1).
Following TDS, DNA was extracted from four rVVs,
potentially containing the BeauR-4/91(S) cDNA. Analysis by
PCR, using GPT-specific primers confirmed the loss of the GPT
gene following the second TDS recombination event in three of
the rVVs. The IBV cDNAs within these rVV DNAs were analysed
for the presence of 4/91 S sequence by amplifying a region
comprising the S gene. Three rVVs, were then further screened by
sequence analysis of different regions of the S1 and S2 subunits of
the chimaeric S gene to confirm that an S gene, with the
ectodomain sequence from IBV 4/91(UK) had been inserted into
the IBV Beaudette genomic sequence lacking an S gene sequence.
All three rVVs were found to contain the sequence corresponding
to the chimaeric S gene, one rVV, rVV-BeauR-4/91(S), was
chosen for further work.
Recovery of infectious rIBVs from the rVVs
The recovery of an infectious rIBV expressing the chimaeric 4/
91 S glycoprotein was attempted using DNA extracted from rVV-
BeauR-4/91(S) in CK cells, previously infected with rFPV/T7, to
provide T7 RNA polymerase, and co-transfected with the rVV
DNA and pCi-Nuc [41] as previously described [27,28]. The
transfected CK cells (P0) were incubated for three days and after
being filtered to remove any rFPV/T7, the supernatant was used
to infect fresh CK cells monolayers. Four days after infection,
supernatant and cells were collected (P1) and analysed by RT-
PCR. After several rescue attempts RT-PCR results showed that
there was no rIBV present in P1, presumably because IBV 4/
91(UK), used as donor of the S gene, is refractory for growth in
CK cells. Therefore, 10-day-old embryos were inoculated with cell
lysate from the transfected P0 CK cells. Allantoic fluid was
collected 48 h post infection from the eggs (EP1) and total RNA
was extracted and analysed by RT-PCR. RT-PCR results were
positive for specific 4/91 S products indicative of infectious rIBV.
Sequence analysis, using oligonucleotides covering a region from
the C-terminus of the replicase gene to the C-terminus of the 3c
coding region of gene 3, confirmed that the S gene was from IBV
4/91(UK). The allantoic fluid was then used for further five
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BeauR-4/91(S) that was used for the subsequent experiments.
Characterisation of rIBV BeauR-4/91(S) for pathogenicity
and homologous protection
In order to test the pathogenicity of BeauR-4/91(S) and to
determine whether the rIBV is able to induce a protective immune
response against challenge with pathogenic 4/91, and to reduce
the number of chickens needed, a single experiment was carried
out to test these two attributes of the rIBV. The first part of the
experiment was to determine whether there were any clinical signs
associated with an IBV infection, such as those we knew were
associated with IBV 4/91(UK). The second part was to challenge
BeauR-4/91(S) vaccinated birds with 4/91(UK) to determine
whether the rIBV could induce homologous protection. This part
of the experiment required infection of birds with pathogenic 4/
91(UK) as a control and was also the control for identifying clinical
signs associated with 4/91(UK) for the pathogenicity part of the
experiment. In addition, we also challenged chickens that had
been vaccinated with BeauR-4/91(S) with a heterologous,
different serotype, pathogenic IBV M41-CK. M41 and Beaudette
belong to the same serogroup, Massachusetts, and as can be seen
from Fig. 2, the S1 part of the M41 S protein sequence differs in a
similar way as Beaudette to the 4/91 sequence. Previous studies
[42] concluded that the Massachusetts-based vaccines tested did
not offer protection against viruses belonging to the 4/91
serogroup.
Analysis of pathogenicity
In order to test the pathogenicity of BeauR-4/91(S), three
groups of 13 8-day-old SPF chickens were inoculated by eye-drop
and intranasally with 3.6 log10 CD50 of BeauR-4/91(S). Another
two groups of 13 birds were infected with 0.1 ml of serum-free
medium as controls. The birds were observed for clinical signs,
snicking, wheezing and nasal discharge, up to 10 days post-
inoculation. Only very low levels of snicking were observed in two
of the groups infected with BeauR-4/91(S), 0.07 and 0.03 per min
per bird on day 6 and 7 after infection in one group and 0.03 per
min per bird on day 6 after infection in the other group, no other
clinical signs were observed (data not shown). In contrast, chickens
infected with pathogenic 4/91(UK) showed clinical signs associ-
ated with IBV from 3 days post infection (Fig. 3A & 3B). These
results showed that replacement of the Beau-R S gene with the S
gene from 4/91(UK) did not confer pathogenicity to the resulting
BeauR-4/91(S) virus.
Analysis of protection induced by BeauR-4/91(S)
Three weeks after the primary inoculation, the chickens were
challenged as follows: of the three groups of chickens previously
infected with BeauR-4/91(S), the Beau-4/91(S): 4/91 group was
challenged with 3.6 log10 CD50 of pathogenic IBV 4/91(UK); the
Beau-4/91(S):M41 group was challenged with 3.6 log10 CD50 of
pathogenic IBV M41-CK; and the Beau-4/91(S):mock group was
mock infected with serum-free medium. Of the two previous
control groups, which had not received a primary inoculation, the
mock:4/91 group was challenged with 3.6 log10 CD50 of
pathogenic IBV 4/91(UK), and the mock:mock group was
challenged with serum-free medium. Observations for clinical
signs were carried out daily on each group from three days post-
infection. In addition, at 4, 5 and 6 days post-infection the tracheas
of three randomly selected chickens from each group were
examined for ciliary activity and the presence of IBV.
As anticipated, the mock:4/91 group of chickens that did not
receive a primary inoculum with Beau-R-4/91(S) and was
subsequently challenged with pathogenic 4/91(UK) showed the
highest levels of clinical signs. Snicking rates peaked at 6 days post-
challenge (Fig. 3A) with the highest score for wheezing observed at
4 days post-challenge (Fig. 3B). Tracheal rales were observed and
one bird showed nasal discharge. Snicking rates differed from 0.6
snicks per min per bird in the mock:4/91 group to 0 snicks on day
6 post-challenge in the BeauR-4/91(S):4/91 group of chickens that
were primarily inoculated with Beau-R-4/91(S) and then chal-
lenged with pathogenic 4/91(UK) (Fig. 3A) and no wheezing was
observed in this group of chickens (Fig. 3B), no other clinical signs,
rales or nasal discharge, were observed; indicating that homolo-
gous protection had been induced by BeauR-4/91(S). As expected,
the control groups, BeauR-4/91(S):mock and mock:mock groups
of chickens did not show any clinical signs (Fig. 3A & B).
Consistent with the clinical signs results, the mock:mock group
of chickens that was neither primarily inoculated with Beau-R-4/
91(S) nor subsequently challenged with a pathogenic IBV showed
ciliary activities .95% on day 4 after inoculation (data not shown).
The BeauR-4/91(S):mock group of chickens that received the
primary inoculation with rIBV BeauR-4/91(S) but was not
challenged also showed .95% ciliary activity on day 4 after
inoculation (data not shown). In contrast, the mock:4/91 group of
chickens that had not been primarily inoculated with Beau-R-4/
91(S) but were challenged with pathogenic IBV 4/91(UK) showed
the lowest level of ciliary activity, ,5% (.95% ciliostasis) on day 4
after challenge with 4/91 (Fig. 3C). The BeauR-4/91(S):4/91
group of chickens that received the primary inoculation with rIBV
Beau-R-4/91(S) and subsequently challenged with pathogenic
IBV 4/91(UK) showed a high retention of ciliary activity, 88%, by
day 6 post-infection when compared to the mock:4/91 group of
chickens (Fig. 3C). In other words, the BeauR-4/91(S):4/91 group
retained most ciliary activity, indicating that prior infection with
BeauR-4/91(S) had induced protection against challenge with
pathogenic 4/91(UK).
The BeauR-4/91(S):M41 group of chickens that were primarily
inoculated with BeauR-4/91(S) and subsequently challenged with
the heterologous serotype of pathogenic IBV M41-CK showed a
maximum of 0.15 snicks per bird per min on day 5 post-challenge
whereas no snicking was observed in the BeauR-4/91(S):4/91
group of chickens (Fig. 3A). Wheezing was observed in 20% of the
BeauR-4/91(S):M41 group of chickens by 5 post-challenge.
Previous work showed that M41-CK caused snicking levels
peaking at day 5 post-infection (1–2 snicks/min/bird) and
wheezing levels of 90%, at day 7 post infection, in infected birds
when compared to an avirulent IBV [1,43]. Therefore, our results
suggested that under experimental conditions BeauR-4/91(S) had
induced some level of cross protection against M41-CK according
to analysis of clinical signs. However, by day 5 post-challenge the
Figure 2. Comparison of the amino acid sequences of the S glycoproteins of IBV strains Beau-R, 4/91(UK) and M41-CK. The sequences
were aligned using ClustalX 2.1 [67] and compared using GeneDoc Multiple Sequence Alignment Editor and Shading Utility version 2.7.001 (http://
www.nrbsc.org/gfx/genedoc). Amino acids shaded in black represent identical amino acid residues found in each sequence; non-highlighted residues
represent differing amino acids. The transition sites between the IBV S glycoprotein domains are marked with an arrow; the signal sequence after
position 18, the S1/S2 junction is after position 539, the TM domain starts at position 1096 and the cytoplasmic tail starts at position 1121. The
ectodomain is composed of amino acids 19–1095 and the endodomain is composed of amino acids 1096–1164.
doi:10.1371/journal.pone.0024352.g002
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(100% ciliostasis), as also observed for the mock:4/91 group of
chickens (Fig. 3C), indicating a poor degree of cross protection
based on analysis of ciliary activity.
In summary, in terms of clinical observations, snicking and
wheezing, birds initially infected with BeauR-4/91(S) and
subsequently challenged with 4/91(UK) virus displayed lower
levels of clinical signs when compared to birds infected with 4/
91(UK) (mock:4/91 group). In contrast, birds inoculated with
BeauR-4/91(S) and subsequently challenged with M41-CK
were not protected to the same extent. The use of clinical
scores and degree of ciliostasis observed, as criteria of
pathogenicity, showed there was a strong degree of protection
induced by primary inoculation with BeauR-4/91(S) against
challenge with homologous pathogenic 4/91(UK) but much
less protection when the BeauR-4/91(S) vaccinated chickens
were challenged with pathogenic M41-CK belonging to the
heterologous serotype. Overall, our results suggest that BeauR-
4/91(S) is able to protect chickens against homologous
challenge with pathogenic 4/91(UK), but offers less cross
protection against challenge with a heterologous serotype such
as IBV M41.
Figure 3. Assessment of clinical signs associated with BeauR-4/91(S)-infected chicks and following challenge with IBV 4/91(UK) or
M41-CK. The groups of chickens were assessed for the clinical signs snicking (A) and wheezing (B) following challenge with IBV 4/91(UK) or M41-CK.
The levels of these clinical signs were significantly reduced in the BeauR-4/91(S):4/91 and BeauR-4/91(S):M41 groups when compared with the
mock:4/91 group (p,0.05). Ciliary activity of the trachea was significantly higher in the BeauR-4/91(S):4/91 group when compared with the control
group mock:4/91, indicative of homologous protection (C). Clinical signs were recorded from days 3 to 7 post-challenge. The birds were observed
individually except for snicking, where they were observed as a group.
doi:10.1371/journal.pone.0024352.g003
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chickens
In order to determine whether there was any virus in the
tracheas of the infected chickens following challenge with
pathogenic IBV, tracheal section homogenates derived from
infected chickens were used to infect TOCs. Tracheal homoge-
nates derived from tracheas taken from chickens belonging to the
mock:4/91, BeauR-4/91(S):4/91 and BeauR-4/91(S):M41 groups
at 4, 5 and 6 days after challenge with pathogenic IBV were
produced and used to infect TOCs, which were subsequently
observed for growth of potential virus as a result of loss of ciliary
activity; loss of ciliary activity, .25% ciliostasis, is indicative of
IBV being present in the tracheal sample isolated from an infected
bird. There was a significant difference (p,0.05) in the ciliary
activity displayed by the control birds, mock:4/91 group,
compared to the two groups of chickens primarily infected with
BeauR-4/91(S) and challenged with either pathogenic IBV 4/
91(UK) or M41-CK (Fig. 4). The average levels for ciliostasis
observed at days 4, 5 and 7 in the TOCs, after infection with
tracheal samples from the challenged birds, were 27625% for the
BeauR-4/91(S):4/91 group and 13611% for the BeauR-4/
91(S):M41 group, whereas an average ciliostasis level of
74615% was observed for the mock:4/91 group (Fig. 4). This
observation suggested that either no challenge virus or very low
levels of challenge virus was present in the tracheas of birds
initially infected with BeauR-4/91(S) and subsequently challenged
with either 4/91(UK) or M41-CK, indicative of the induction of
protective immunity by BeauR-4/91(S), including some cross
protection.
Analysis of IBV-RNA present in the tracheas of infected
chickens
To check for the presence of 4/91- or M41-derived RNA in the
tracheal epithelial cells from the infected chickens following
challenge with pathogenic IBV, total RNA was isolated from the
epithelial cells and analysed by qRT-PCR. Analysis of the tracheas
from the birds belonging to the mock:4/91 group showed they all
had IBV-derived RNA present (Table 1). Subsequent sequence
analysis confirmed that the IBV RNA present corresponded to
pathogenic IBV 4/91(UK). With the exception of one bird, no
IBV-derived RNA was detected in the tracheas of birds belonging
to the BeauR-4/91(S):4/91 group (Table 1). These results are
consistent with the clinical signs observations and with the ciliary
activity levels displayed by TOCs infected with the corresponding
trachea-derived suspensions prepared from infected chickens and
indicate that Beau-R-4/91(S) induced protection against subse-
quent challenge with pathogenic IBV 4/91(UK). Interestingly,
IBV RNA was also only detected in one of the birds belonging to
the BeauR-4/91(S):M41 group (Table 1) indicative of some cross
protection. Sequence analysis of the RT-PCR product from this
sample confirmed that the RNA was derived from M41-CK. This
result supports the virus re-isolation results in which infectious IBV
was detected in TOCs following infection with tracheal extracts
derived from birds sampled from this group.
Discussion
We have previously constructed a rIBV, BeauR-M41(S),
containing the S glycoprotein ectodomain of the pathogenic IBV
strain M41-CK within the genomic context of the apathogenic
strain, IBV Beau-R, both viruses belong to the same Massachusetts
serotype [30]. BeauR-M41(S) was found to acquire the cellular
tropism of M41-CK, but remained apathogenic, according to
clinical signs, in infected birds [1]. Importantly, birds inoculated
with BeauR-M41(S) showed increased levels of protection, when
compared to Beau-R, against challenge with M41-CK virus,
suggesting that the ectodomain region of the S protein is important
in inducing protective immunity in chickens against IBV infection,
and therefore represents a region that should be explored in more
detail for effective IBV vaccine development. To extend this work,
we replaced the ectodomain region of the Beaudette S gene with
the sequence of another pathogenic IBV strain, 4/91(UK), which
belongs to a different serotype, the 793/B serotype. The first
known virus of this IBV serotype was isolated in France in 1985
[44]. In the UK, IBV 4/91 (also known as 793/B and CR88)
Figure 4. Ciliary activity levels displayed by TOCs infected with
trachea-derived suspensions taken from birds infected with
BeauR-4/91(S) and challenged with 4/91(UK) or M41-CK
compared with non-vaccinated but challenged birds. Ciliary
activity levels were significantly higher in BeauR-4/91(S):4/91 and
BeauR-4/91(S):M41 groups when compared with mock:4/91 group on
each day (p,0.05). Ciliary activity was observed on days 4 (A), 5 (B) and
7 (C) following infection of the TOCs. Each data point represents the
average of the readings of TOCs infected with tracheal samples from
three birds taken on days 4, 5 and 6 after challenge (average
percentage of six TOCs per bird).
doi:10.1371/journal.pone.0024352.g004
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[6,42,45] and were subsequently found to be a common pathogen
in flocks of chickens in many parts of Western Europe and
elsewhere by the late 1990s [46]. Despite the availability of an
attenuated vaccine against 4/91 serotype viruses, recent studies
suggest that viruses belonging to the 4/91 serogroup are still
prevalent in European flocks [47–50] and that their continued
presence is still an important concern for the poultry industries in
many different countries [6].
The rIBV BeauR-4/91(S) grew in eggs and in TOCs, but was
not able to produce infectious virus in CK cells suggesting that it
acquired the tropism characteristics of the IBV donor strain 4/
91(UK), which unlike Beau-R, is refractory for replication in CK
cells, providing further evidence that the S protein is the major
determinant of tropism and host range. These results support those
from our previous work in which the ectodomain of the S gene in
Beaudette was replaced with that from an IBV strain of the same
serotype, M41-CK. The recombinant IBV, BeauR-M41(S), was
shown to have its in vitro host range restricted to those cells in
which M41-CK could grow [30].
Similar to the observations with BeauR-M41(S), our results
showed that BeauR-4/91(S) was also apathogenic, supporting our
previous observation that an S gene from a pathogenic strain, even
from a different serotype, is not sufficient to confer pathogenicity.
Consistent with these findings, pathogenicity studies done with a
chimaeric IBV in which the replicase gene was from the
apathogenic IBV Beaudette, but the rest of the genome was from
the pathogenic M41-CK strain, showed that this chimaeric virus
was still not pathogenic, indicating that determinants of pathoge-
nicity reside within the replicase gene [43].
Work by others has shown that IBV H120, a major
Massachusetts serotype vaccine, induced poor protection against
challenge with a 4/91 virus [42]. The amino acid sequences of the
S proteins of Beau-R and 4/91(UK) differ by 25% and 11% for
the S1 and S2 subunits, respectively. Since it is the S1 subunit that
induces virus neutralising antibodies and protective immune
responses [51–54], this suggests that the ability to induce
protective responses against 4/91 may reside in some of the
25% amino acid differences between this strain and Beau-R.
Similar to our results for BeauR-M41(S), our protection studies in
this work showed that BeauR-4/91(S), which contains the 4/
91(UK) S protein ectodomain (comprising S1 and most of S2),
conferred protection against challenge with 4/91(UK). The
criteria used to measure pathogenicity were observation of clinical
signs (snicking, wheezing), ciliary activity in the trachea, presence
of virus-derived RNA (by qRT-PCR) in tracheas and virus
isolation from tracheal samples. According to clinical signs
observations, prior inoculation of chickens with BeauR-4/91(S)
resulted in protection against challenge with 4/91(UK). Analysis of
the tracheas from the BeauR-4/91(S):4/91 challenge group of
chickens showed a significant retention of ciliary activity levels
when compared to the very low levels of ciliary activity observed in
tracheal samples from the mock:4/91 group. This observation was
supported by qRT-PCR analysis on RNA extracted from trachea
samples. Only one chicken was positive for the detection of viral
RNA in the trachea samples from chickens in the BeauR-4/
91(S):4/91 challenge group. Furthermore, there was clearly a
reduction in the levels of ciliostasis displayed by TOCs infected
with potential virus present in tracheal suspensions prepared from
the BeauR-4/91(S):4/91 group when compared to the mock:4/91
group. Interestingly, comparison of the data indicated there was
more ciliostasis observed from tracheal samples from the BeauR-
4/91(S):M41 group than the BeauR-4/91(S):4/91 group, howev-
er, the overall level of ciliostasis observed from either group is
outside the level expected for presence of virus. The degree of
cross protection among different IBV serotypes is generally low
and decreases as the amino acid differences between the S protein
increases [55,56]. By replacing the S gene of the apathogenic
Beau-R, from the Massachusetts serotype, with that from 4/
91(UK), from the 793/B serotype, we have produced an
apathogenic virus that induces protection against challenge with
a pathogenic virus from a different serotype, 4/91(UK). Demon-
strating and confirming that serotype is associated exclusively with
the S glycoprotein irrespective of the genotype of the IBV strain.
Although challenge of BeauR-4/91(S) vaccinated birds with
M41-CK resulted in ciliostasis, observation of clinical signs, qRT-
PCR and virus isolation suggested there was a low level of
protection against challenge with the heterologous M41-CK, even
though 4/91(UK) and M41-CK are from different serotypes. In
our previous work, Hodgson et al. [1], we similarly showed that no
virus was recovered from the tracheas of chickens inoculated with
Beau-R and challenged with M41-CK, even though the level of
ciliostasis was high (.80%). Most IBV serotypes differ by 20% to
25% from each other in the S1 sequence at amino acid level [57–
62], some differing only by 2% [63]. The S1 subunit of M41-CK
and 4/91(UK) differ by 25.5% at the amino acid level. Although
cross protection amongst different serotypes is generally poor,
some cross protection between different serotypes has been
observed previously. An IBV 4/91 vaccine was shown to protect
against challenge (as judged by retention of ciliary activity) with
heterologous serotypes Arkansas, D207 and the Brazilian isolates
50/96, 57/96, 62/96 and 64/96. However, no protection was
observed against challenge with M41, as judged by loss of ciliary
activity, clinical signs and virus isolation wee not assessed [64]. In
addition, the IBV vaccine H120 conferred some protection against
challenge viruses, from the Belgium B1648, French 84084 and
French 84221 serotypes of IBV [64]. Some heterologous
protection against M41 was observed in birds vaccinated with
the heterologous serotype UK/6/82, despite the 20% difference in
S1 [55]. Vaccination with TM-86w, classified as a JP-II genotype
on the basis of the sequence of the N-terminus of the spike protein,
conferred protection against challenge with 4/91, despite being
classified as being a different genotype, as indicated by respiratory
symptoms, ciliostasis and virus re-isolation from tracheal swabs
[65].
Although we did not include a mock:M41 control group, the
levels of snicking and wheezing observed in the BeauR-4/
91(S):M41 group were less than would have been expected from
a mock:M41 group as observed from previous experiments [1,43],
Table 1. Detection of IBV-derived RNA by qRT-PCR in tracheal
samples from birds used in the protection study.
Virus Combination Day 4 Day 5 Day 6
Vaccine BeauR-4/91(S):Challenge M41-CK 1/3 0/3 0/3
Vaccine BeauR-4/91(S):Challenge 4/91(UK) 1/3 0/3 0/3
Mock:Challenge 4/91(UK) + + +
Notes: Tracheas from three birds per group were removed 4, 5 and 6 days after
challenge and kept in RNAlaterH. After disruption and homogenisation, RNA
was extracted and used as a template for IBV-specific qRT-PCR. Trachea samples
were taken from three different birds each day (n=9), for the control group
(mock:4/91) tracheas were taken from one bird per day (n=3) for assessment.
All reactions were performed in triplicate in a 7500FAST Taqman machine.
Amplification plots were analysed using Applied Biosystems SDS software. The
qRT-PCR method used in this manuscript has previously been assessed for
sensitivity, maximum sensitivity being of 100 copies [40].
doi:10.1371/journal.pone.0024352.t001
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by the results of virus re-isolation and analysis of viral RNA by
qRT-PCR. Interestingly, although vaccination with BeauR-4/
91(S) did induce a degree of cross protection against challenge with
M41-CK, as judged by reduced clinical signs, no virus isolation
and no detection of viral RNA, there was extensive loss of ciliary
activity. We also observed this phenomenon in our previous work
when birds vaccinated with Beau-R had been challenged with
M41-CK [1]. Work by Marquardt et al. [66] showed that virus was
isolated from tracheas exhibiting ciliostasis following a heterolo-
gous challenge. However, up to three passages in TOCs was
required to reveal the presence of virus, indicating that the amount
of virus present in the tracheas had been very low. We can only
speculate why heterologous vaccination sometimes results in
protection, as judged by reduced clinical signs and absence of
detectable virus in the trachea whilst at the same time appearing
not to have induced protection against heterologous challenge,
when based on loss of ciliary activity (ciliostasis). Retention of
tracheal ciliary activity has long been used to assess cross
protection [55,64]. Our finding and those of Marquardt et al.
[66] do not argue against the use of this criterion as a correlate of
protection. The importance of an intact respiratory epithelium
would be manifest more in the field than under laboratory
conditions. Partial cross protection, based on clinical signs and
virus recovery, observed in experiments performed under
laboratory conditions in experimental animal facilities would be
expected to be sometimes insufficient to protect against economic
losses in the field. The damage to the respiratory epithelium, as
reflected by observation of ciliostasis, would enable pathogenic
strains of bacteria e.g. E.coli, when present, to cause additional
pathology.
Our previous work used a rIBV expressing a heterologous S
glycoprotein from IBV M41-CK that belongs to the same
serogroup as the recipient virus, Beau-R, which differs by only
5% with respect to the amino acid sequence. We have now
extended this work by demonstrating that expression of an
heterologous S glycoprotein from a different serogroup, which
differs by 25% in the amino acid sequence to either Beau-R or
M41-CK S glycoproteins, conferred homologous protection
against challenge with pathogenic 4/91(UK). In addition,
according to clinical signs, detection of virus RNA and re-isolation
of virus there was a degree of heterologous protection, under
experimental conditions, against challenge with M41-CK, an IBV
isolate from a different serotype.
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